[EN] COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS<br/>[FR] COMPOSITIONS ET MÉTHODES DESTINÉES À RÉDUIRE LES ERREURS DE MÉDICATION
申请人:AZHC LLC
公开号:WO2019014420A1
公开(公告)日:2019-01-17
The present disclosure provides for a method of decreasing medication errors by adding an odorant to a pharmaceutical composition comprising an active agent. The odorant has a distinct and characteristic odor. Thus, the pharmaceutical composition comprising the active agent can be properly identified by the characteristic odor.
[EN] PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES DÉRIVÉS DE POH
申请人:NEONC TECH INC
公开号:WO2021061752A1
公开(公告)日:2021-04-01
The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).
[EN] TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL<br/>[FR] TRAITEMENT DU GLIOBLASTOME RÉCURRENT AVEC DE L'ALCOOL PÉRILLIQUE
申请人:NEONC TECH INC
公开号:WO2022104041A1
公开(公告)日:2022-05-19
The present invention provides an intranasal glioblastoma therapy with purified perillyl alcohol. Patients with recurrent glioblastoma when treated with perillyl alcohol purified by tge disclosed methods showed improved survival when compared to historical controls. Glioblastoma patients with an isocitrate dehydrogenase 1 (IDH1)-mutation showed improved survival when compared with wild-type IDH patients.
A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.
The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.